Renal replacement therapy improved median survival vs conservative management overall (67.1 vs 21.2 months; P<0.001), but the advantage was small and non-significant in patients >75 years.
Cohort (n=844)
Absolute Event Rate: 67.1% vs 21.2%
p-value: p=< 0.001
BACKGROUND: Elderly patients with end-stage renal disease and severe extra-renal comorbidity have a poor prognosis on renal replacement therapy (RRT) and may opt to be managed conservatively (CM). Information on the survival of patients on this mode of therapy is limited. METHODS: We studied survival in a large cohort of CM patients in comparison to patients who received RRT. RESULTS: Over an 18-year period, we studied 844 patients, 689 (82%) of whom had been treated by RRT and 155 (18%) were CM. CM patients were older and a greater proportion had high comorbidity. Median survival from entry into stage 5 chronic kidney disease was less in CM than in RRT (21.2 vs 67.1 months: P 75 years when corrected for age, high comorbidity and diabetes, the survival advantage from RRT was ~ 4 months, which was not statistically significant. Increasing age, the presence of high comorbidity and the presence of diabetes were independent determinants of poorer survival in RRT patients. In CM patients, however, age > 75 years and female gender independently predicted better survival. CONCLUSIONS: In patients aged > 75 years with high extra-renal comorbidity, the survival advantage conferred by RRT over CM is likely to be small. Age > 75 years and female gender predicted better survival in CM patients. The reasons for this are unclear.
Chandna et al. (Mon,) conducted a cohort in Stage 5 chronic kidney disease (n=844). Renal replacement therapy vs. Conservative management was evaluated on Median survival from entry into stage 5 chronic kidney disease (p=< 0.001). Renal replacement therapy improved median survival vs conservative management overall (67.1 vs 21.2 months; P<0.001), but the advantage was small and non-significant in patients >75 years.